News | February 04, 2013

Elekta Supports First Patient Treated with Carbon Ion Therapy at Italian Cancer Center

Elekta Mosaiq Radiation Oncology Information System Centro Nazionale di Adrotera

February 4, 2013 — The need for flawless coordination of its carbon ion treatments led officials at the CNAO Foundation (Centro Nazionale di Adroterapia Oncologica) to choose Elekta’s Mosaiq Oncology Information Management System. On Nov. 13, the CNAO Foundation became the world’s first center to use Mosaiq to guide a cancer patient’s carbon ion therapy. CNAO — which made news last year when it treated its first patient with proton therapy — is now nearing completion of its National Center of Oncological Hadrontherapy.

Dr. Sandro Rossi, general manager and technical director of the CNAO Foundation, says that after an initial start up phase the center will be running double shifts, treating 150 to 200 patients a month with both proton therapy and carbon ion therapy.

Using Mosaiq, which incorporates its record and verify module for particle therapy accelerator technology, CNAO will store and retrieve data related to particle therapy treatment and follow-up care for patients, as well as the center’s cancer care and treatment research. “In our daily routine, Mosaiq has helped us schedule procedures and facilitate more efficient workflow for our clinical and scientific research activities,” Rossi explains.

A specific advantage of carbon ion treatments is the possibility to prescribe and report physical and biological doses differently than other therapies, and the necessity to schedule pre-positioning procedures to optimize patient throughput. Elekta has demonstrated its commitment to work with CNAO to extend Mosaiq capabilities to operate within this environment. Combined with the flexibility that Mosaiq demonstrates, this was a strong selling point for CNAO, according to Rossi.

“A very compelling Mosaiq feature is the possibility to integrate, expand and fine tune the solution to include the different procedures that will be developed during the working life of a facility like CNAO,” he says. “The use of Mosaiq also will lead to a high level of optimization of staffing activities.”

“Embracing the ability to extend our particle therapy offering to incorporate carbon ions was a first for Elekta and one that we are excited to be undertaking with CNAO,” says Todd Powell, executive vice president, Elekta Software. “Our success in this area will further advance our solution and reinforce our market leadership as a provider of patient management solutions within particle therapy.”

For more information: www.elekta.com

Related Content

A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.